null

null

null

null

null

null

null

null

null

null

null

null

null

null

Minimal debt; cash-funded biotech with ~$300M+ cash runway; near-zero leverage ratio; interest rate hikes marginally increase cash yield on reserves

Low sensitivity; no material floating-rate debt; higher rates modestly benefit cash holdings; primary risk is discount rate impact on DCF valuation

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

AAV capsid manufacturing (single-source CDMOs) and specialized raw biologics from U.S./EU suppliers; no significant geopolitical chokepoint beyond CDMO concentration

Minimal international revenue; U.S.-centric clinical stage company; negligible sovereign currency devaluation exposure across markets

Primarily U.S.-based operations; Cambridge, MA HQ; no meaningful foreign revenue streams; currency devaluation risk is effectively null

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on select AAV manufacturing CDMOs (e.g., Brammer Bio/Thermo Fisher); single-vendor concentration likely exceeds 30% of manufacturing input cost

Biotech R&D/licensing; cloud disruption would impair informatics and collaboration tools but not core gene therapy manufacturing or clinical operations

Partnership/collaboration revenue model; cloud termination would cause operational disruption but core wet-lab and CDMO-based operations would continue

Low API coupling risk; uses standard bioinformatics and SaaS tools; no proprietary API lock-in identified; switching costs are moderate for internal data platforms

Not applicable; equity-funded biotech with milestone/royalty revenue; no token or investment contract structure; Howey Test risk is negligible

Very High

Low GDPR/CCPA exposure; handles clinical trial patient data under IRB/FDA frameworks; limited consumer data; compliance infrastructure standard for U.S. clinical-stage biotech

Minimal antitrust risk; small-cap clinical-stage company with no dominant market position; gene therapy market is nascent and fragmented

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% non-recurring; revenue derives from collaboration milestones and upfront payments (Novartis, AbbVie deals); no subscription or retainer structure

Collaboration agreements and licensing milestones from pharma partners (Novartis, AbbVie); future royalties on approved products if pipeline succeeds

No commercial product pricing yet; partnership deal terms set by negotiation with large pharma; pricing power determined by clinical data strength and AAV platform differentiation

Moderate; proprietary TRACER AAV capsid discovery platform provides negotiating leverage, but large pharma partners hold significant pricing authority in deal structures

R&D stage; collaboration revenue margins vary widely; commercial-stage gene therapies historically 70–85% gross margin; current margins not meaningful

No free-rider risk; proprietary gene therapy IP is protected; platform access gated by licensing agreements with enforced exclusivity provisions

Headcount-linear to sublinear; doubling pipeline throughput requires incremental scientific staff but platform leverage allows some sublinear scaling in discovery phase

Moderate marginal cost; additional pipeline programs require incremental CDMO capacity, regulatory, and clinical staff but platform amortizes across programs

Not applicable; not a franchise business model

At 10x scale (multiple approved products), CAC shifts to pharma BD relationships; unit economics depend on royalty rates (typically 5–15%) on blockbuster gene therapy products

Weak network effects; proprietary capsid data library (TRACER) improves with more screening data, creating a mild data flywheel but no traditional network effect

-47.4% Return on Assets (Negative equity)

Moderate resilience; milestone payments from large pharma partners provide near-term buffer; clinical-stage funding dependent on capital markets which are recession-sensitive

Large pharmaceutical companies (Novartis, AbbVie) as collaboration partners; high concentration risk with top 2 partners representing majority of contracted revenue

Future commercial customers would be hospital systems and specialty pharmacies; currently no secondary commercial customer segment

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

6.4% CapEx / Revenue (Moderate-CapEx)

0001640266

VYGR